Trial Profile
The RAIN Study, a Multicenter Randomized Double-blind Phase 2b Study of NEOD001 in Previously Treated Subjects With Systemic Light-chain (AL) Amyloidosis and Persistent Renal Involvement
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2024
Price :
$35
*
At a glance
- Drugs Birtamimab (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- Acronyms RAIN
- 12 Dec 2023 Results of an analysis assessing histologic and molecular findings using renal biopsies from participants from this trial before randomization to NEOD001 or placebo presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 23 Apr 2018 According to a Prothena media release, based on the results of PRONTO study, the independent data monitoring committee reviewed a futility analysis of the VITAL study and recommended a discontinuation of the VITAL study as well as the open label extension studies for futility.
- 23 Apr 2018 Status changed from recruiting to discontinued, according to a Prothena media release.